Differing assumptions drive competition among liposome companies

Last of two parts

The three companies developing liposomal drugs to treat cancer provide a neat case history of the strategic marketing choices companies make when they design clinical trials. While the final verdict isn't in on who will win the race, all three have chosen different means to the same end...